Sector: Health Care
Director information for LIGAND PHARMACEUTICALS INC
Board as disclosed in the proxy statement filed April 21, 2026. Titles and roles are as stated in that filing and may have changed since.
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Jason Haas | Chief Financial Officer of Odyssey Therapeutics | 58 | ["Former Chief Financial Officer of Syros Pharmaceuticals","Former Co-Head of Americas, Healthcare Investment Banking at Barclays"] | [] | 2026 |
| Jason M. Aryeh | Founder and Managing General Partner of JALAA Equities, LP | 57 | [] | [] | 2026 |
| John L. LaMattina, Ph.D. | Senior Partner and Board Member at PureTech Health | 76 | ["Former President for Pfizer Global R&D"] | [] | 2026 |
| John W. Kozarich, Ph.D. | Co-Founder and Chief Executive Officer of Paludatus Pharmaceuticals | 76 | ["Former Chairman and President of ActivX Biosciences","Former Vice President for Merck Research Laboratories"] | [] | 2026 |
| Martine Zimmermann, Pharm.D. | Executive VP of Regulatory Affairs and Quality Assurance at Inventiva Pharma | 57 | [] | [] | 2026 |
| Nancy Ryan Gray, Ph.D. | President and Chief Executive Officer of Gordon Research Conferences | 66 | [] | [] | 2026 |
| Stephen L. Sabba, M.D. | Leading BioPharma Analyst and Fund Manager for Knott Partners, L.P. | 66 | [] | [] | 2026 |
| Todd C. Davis | Chief Executive Officer of Ligand Pharmaceuticals Incorporated | 65 | ["Co-Founder and Former Managing Partner of HealthCare Royalty Partners (now HCRx)"] | [] | 2026 |
